Evidence map›Paper›PMID 28690529›Full record

ArticleCase reports in oncology

Successful Treatment of Richter Transformation with Ibrutinib in a Patient with Chronic Lymphocytic Leukemia following Allogeneic Hematopoietic Stem Cell Transplant.

Samip Master, Cheri Leary, Amol Takalkar, James Coltelingam, Richard Mansour, Glenn M Mills, Nebu Koshy

Open access · goldAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Case reports in oncology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
0.8field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 12 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Richter Syndrome.Current oncology reports · 2021
    Review
  6. Review
  7. Article
  8. Current trends in the management of Richter's syndrome.International journal of hematologic oncology · 2018
    Review
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Samip MasterLouisiana State University Health Sciences Center, Shreveport, Louisiana, USA.
Cheri LearyLouisiana State University Health Sciences Center, Shreveport, Louisiana, USA.
Amol TakalkarLouisiana State University Health Sciences Center, Shreveport, Louisiana, USA.
James ColtelingamLouisiana State University Health Sciences Center, Shreveport, Louisiana, USA.
Richard MansourLouisiana State University Health Sciences Center, Shreveport, Louisiana, USA.
Glenn M MillsLouisiana State University Health Sciences Center, Shreveport, Louisiana, USA.
Nebu KoshyLouisiana State University Health Sciences Center, Shreveport, Louisiana, USA.
Louisiana State University Health Sciences Center Shreveport · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Patients with chronic lymphocytic leukemia (CLL) who progress to Richter transformation (RT) have a poor prognosis. Multi-agent chemotherapy regimens do not have good response rates. There are few case reports on the use of ibrutinib in RT. Here, we present a patient who was heavily pretreated for CLL, including allogeneic stem cell transplant, and progressed to RT. She had a mixed response to multi-agent chemotherapy and was started on ibrutinib. She had a complete response for 16 months on single-agent ibrutinib with minimal toxicity.

Indexed as

Chronic lymphocytic leukemiaIbrutinibIbrutinib after allogeneic transplantRichter transformation

Identifiers

PMID28690529
PMCPMC5498945
OpenAlexW2657334186

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.